- Home
- MREO vs ELUT Comparison
MREO vs ELUT Comparison
Compare MREO & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | ELUT |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 42.5M |
| IPO Year | 2017 | 2020 |
Fundamental Metrics
Financial Performance| Metric | MREO | ELUT |
|---|---|---|
| Price | $0.31 | $0.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $1.50 | ★ $6.00 |
| AVG Volume (30 Days) | ★ 4.9M | 47.1K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.67 | ★ 146.77 |
| EPS | ★ N/A | N/A |
| Revenue | $500,000.00 | ★ $12,293,000.00 |
| Revenue This Year | $5,184.20 | N/A |
| Revenue Next Year | $55.51 | $10.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.20 | $0.50 |
| 52 Week High | $2.37 | $2.50 |
Technical Indicators
Market Signals| Indicator | MREO | ELUT |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 55.21 |
| Support Level | $0.28 | $0.86 |
| Resistance Level | $0.35 | $1.00 |
| Average True Range (ATR) | 0.03 | 0.07 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 40.48 | 76.68 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.